載入中
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
前收盤價
US$6.25
−US$0.16 · -2.50%
盤中時間採用ET。市場資料可能有所延遲。
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
日內區間
目前US$6.25
52週區間
目前US$6.25
盤中時間採用ET。市場資料可能有所延遲。
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
日內區間
目前US$6.25
52週區間
目前US$6.25
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 |
|---|---|---|---|
| 營收 | 1300萬 USD | 700萬 USD | 500萬 USD |
| 銷貨成本 | — | 128.7萬 USD | 100萬 USD |
| 毛利 | 1300萬 USD | 571.3萬 USD | 400萬 USD |
| 研究與開發 | 7404.2萬 USD | 6424.4萬 USD | 3199.7萬 USD |
| 銷售、一般及管理費用 | 2002.9萬 USD | 1148.2萬 USD | 985.3萬 USD |
| 營業費用 | 9407.1萬 USD | 7572.6萬 USD | 4185萬 USD |
| 利息收入 | 332.3萬 USD | 324.2萬 USD | 385.6萬 USD |
| 利息支出 | — | 3.4萬 USD | 5.8萬 USD |
| 折舊和攤銷 | 138.9萬 USD | 128.7萬 USD | 100萬 USD |
| 營業利益 | −8107.1萬 USD | −7001.3萬 USD | −3785萬 USD |
| 淨利 | −6887萬 USD | −6680.8萬 USD | −3405.3萬 USD |
公司資料更新於 2026年10月11日。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$27.83
上漲空間 345.28%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI935.66萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM254.18萬0.00%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF160.21萬0.00%954億 USD0.05%US$235+0.80%
Fidelity Enhanced Small Cap ETFFESM97.24萬0.01%64.1億 USD0.28%US$45.46+0.46%
Vanguard Russell 2000 ETFVTWO92.37萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Russell 2000 Growth ETFIWO91.97萬0.01%139.17億 USD0.24%US$356.78+0.94%
Schwab U.S. Small-Cap ETFSCHA73.09萬0.00%218.24億 USD0.03%US$32.79+0.40%
Vanguard Health Care ETFVHT37萬0.00%220億 USD0.09%US$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
